moxifloxacin has been researched along with Fasting Hypoglycemia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CH; Chou, HW; Lai, MS; Lee, JJ; Shau, WY; Wang, JL | 1 |
| Qiu, HY; Shi, TT; Yang, FY; Yang, JK; Yuan, SS | 1 |
| Basak, P; Batra, A; Blum, D; Jesmajian, S; Kapoor, R; Lakshmi, K; Varma, N | 1 |
| Absi, M; Ghareeb, H; Khalil, A; Ruegg, UT | 1 |
| Mandavia, DR; Patel, TK; Tripathi, CB; Virpariya, MM | 1 |
| Choudhri, S; Gavin, JR; Gross, R; Himmel, H; Kubin, R; Kubitza, D; Meyer, JM | 1 |
| Cornish, W; Knowles, S; Phillips, EJ; Rachlis, A; Simor, AE; Tailor, SA | 1 |
| Catero, M | 1 |
1 review(s) available for moxifloxacin and Fasting Hypoglycemia
| Article | Year |
|---|---|
Dysglycemia and fluoroquinolones: are you putting patients at risk?
Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Evidence-Based Medicine; Family Practice; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Incidence; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; United States; United States Food and Drug Administration | 2007 |
7 other study(ies) available for moxifloxacin and Fasting Hypoglycemia
| Article | Year |
|---|---|
Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cohort Studies; Diabetes Complications; Female; Fluoroquinolones; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Middle Aged; Moxifloxacin; Odds Ratio; Propensity Score; Quinolines; Taiwan | 2013 |
HERG Protein Plays a Role in Moxifloxacin-Induced Hypoglycemia.
Topics: Animals; Blood Glucose; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Glucose Tolerance Test; HEK293 Cells; Humans; Hypoglycemia; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Knockout; Moxifloxacin | 2016 |
Life-threatening hypoglycemia with moxifloxacin in a dialysis patient.
Topics: Aged; Anti-Bacterial Agents; Fluoroquinolones; Humans; Hypoglycemia; Kidney Failure, Chronic; Male; Moxifloxacin; Renal Dialysis | 2012 |
The effect of levofloxacin and moxifloxacin on cardiovascular functions of rats with streptozotocin-induced diabetes.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Biological Factors; Blood Glucose; Bradycardia; Cardiovascular System; Diabetes Mellitus, Experimental; Electrocardiography; Endothelium, Vascular; Fluoroquinolones; Heart; Heart Rate; Hypoglycemia; Intermediate-Conductance Calcium-Activated Potassium Channels; Levofloxacin; Male; Mesenteric Arteries; Moxifloxacin; Ofloxacin; Quinolines; Rats; Rats, Wistar; Small-Conductance Calcium-Activated Potassium Channels; Streptozocin | 2013 |
Moxifloxacin-induced hypoglycemia in a non-diabetic patient.
Topics: Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Humans; Hypoglycemia; Middle Aged; Moxifloxacin; Quinolines | 2012 |
Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Fluoroquinolones; Glucose; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Male; Moxifloxacin; Product Surveillance, Postmarketing; Quinolines; Rats | 2004 |
Glucose homeostasis abnormalities and gatifloxacin.
Topics: Aza Compounds; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Hyperglycemia; Hypoglycemia; Moxifloxacin; Ofloxacin; Quinolines | 2006 |